Drugs / Zirconium Zr 89-DFO-YS5
Zirconium Zr 89-DFO-YS5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05892393 | Jun 2023 → Aug 2026 overdue | plasma cell myeloma | University of California, San Francisco | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zirconium Zr 89-DFO-YS5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05892393 ↗ |
| Modality | Diagnostic / imaging agent | “an imaging agent called a radiopharmaceutical tracer” NCT05892393 ↗ |
| Route | Intravenous | “Participants receive \[89Zr\]DFO-YS5 intravenously” NCT05892393 ↗ |